Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.

Srinivas Rao

Florian Brand

Christian Angermayer

Lars Christian Wilde

Atai Life Sciences N.V.

Valis Bioscience focuses on improving the measurement and treatment of psychiatric and neurological disorders. The company specializes in psychedelic trials and rare and orphan disorders, developing tools for clinical trials and digital therapeutics.

Valis Bioscience

D11Z Ventures appears to be a venture capital or investment firm, based on their branding and website structure.

Metric
Company Name	Atai Life Sciences N.V.	Valis Bioscience	D11Z Ventures
Symbol	ATAI
MSH ID	LIFE:ATAI	COM:VALISBIOSCIENCE	DE:ZF-HN
Market	STOCKS	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare & Health Services	Financial Services & Finance
Industry	Biotechnology	Clinical Research	Venture Capital
Country	DE	US	DE
Stage
Employee Count	83		11
Website	atai.life	valisbioscience.com	zf-hn.de
LinkedIn		valisbioscience
Founders

Metric
Market Cap	220.98M
Enterprise Value
Monthly Web Traffic		5.74K
Web Traffic Growth		9.98
Valuation
Raised Capital

Metric
Revenue	314.00K
Revenue (LTM)
Revenue (NTM)
Gross Profit	-5K
EBITDA	-125.15M
Operating Income	-125.47M
Net Income	-40.22M
EPS	-0.25
Diluted EPS	-0.25
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.32
Operating Profit Margin	-291.29
EBITDA Margin	-398.57
Net Profit Margin	-122.03
Return on Equity	-0.14
Return on Assets	-0.13
Return on Capital Employed	-0.45

LIFE:ATAI

atai Life Sciences

Last Close

1.52

22/11 21:00

Market Cap

220.98M

Beta: -

Volume Today

2.09M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-4.03
P/B Ratio	1.02
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	1.95K
EV Multiple	-1.78

Metric
Days Sales Outstanding	1.66K
Days Payables Outstanding
Days Inventory Outstanding	0.00
Operating Cycle	11.66K
Cash Conversion Cycle	7.57K
Asset Turnover	0.00

Metric
Operating Cash Flow	-84.12M
Free Cash Flow	-84.71M
Cash Flow to Debt	-4.26
Operating Cash Flow/Sales	-206.82
Free Cash Flow Yield	-0.32

Metric
Cash & Equivalents	45.03M
Accounts Receivable	-2.01M
Inventory	1
Goodwill
Debt to Capitalization	0.10
Debt to Assets	0.05
Current Ratio	11.04
Quick Ratio	10.69

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	113.22
R&D to Revenue	209.35
SG&A to Revenue	179.30